

INDUSTRY HIV VACCINE INVOLVEMENT 2007*

COMPANY	VACCINE CONCEPT	STATUS
AlphaVax	Venezuelan Equine Encephalitis (VEE) vector	Phase I
Avant	Virus-like particles	Pre-clinical
Aventis Pharmaceuticals	Lipopeptide	Phase II
Epimmune	Protein	Phase I
EpiVax	Epitope mapping	Pre-clinical
GenVec	Adenovector technology	Preclinical
GeoVax	DNA/MVA vector	Pre-clinical
GlaxoSmithKline Biologicals	Protein	Phase I
	Measles vector	Pre-clinical
	Non-human primate adenovirus vector	Pre-clinical
	DNA with adjuvant	Phase I
Juvaris Biotherapeutics	Inactivated simian immunodeficiency virus	Pre-clinical
Merck	Adenovirus vector	Phase IIB
	DNA	Phase I
Novartis Vaccines	Alphavirus vector	Phase I
	Live adenovirus vector	Pre-clinical
	Tat protein	Phase I
	DNA/Protein	Phase II
Sanofi Pasteur	Canarypox (ALVAC)/ AIDSVAX.	Proof of concept efficacy trial
	DNA /vaccinia virus (NYVAC)	Phase I
	Canarypox (ALVAC)/peptide	Phase I
Therion	MVA vector	Phase I
	Fowlpox vector	Pre-clinical
United Biomedical	Peptide	Pre-clinical
Wyeth	DNA plasmid cytokine	Phase I
	Vesicular stomatitis virus (VSV) vector	Pre-clinical

* This table represents a selection of the industry and biotech work on AIDS vaccines taken from interviews and public records. Additional companies working in the field are listed in table 2. AVAC welcomes updates and additions. Please send them to avac@avac.org.